Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Canopy Growth CorporationNASDAQ: CGC

Other Income / Expenses · Q4 FY2025 · quarter ended Mar 2026

Other income / expenses remains negative

Q4 FY2025 other income / expenses was -CA$130.49M, compared with -CA$202.9M a year earlier. Trailing-twelve-month other income / expenses was -CA$182.91M.

Context

  • Other income / expenses amounted to 20.9% of revenue in FY2025, down 157.5 pp from a year earlier.
  • Other income / expenses grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -CA$130.49M or moves back toward the trailing-twelve-month quarterly average of -CA$45.73M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$130.49M-164.8% QoQ
Last fiscal yearMar 2026
-CA$101.23M+78.9% YoY
LTMMar 2026
-CA$182.91M+61.9% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+35.7%——
1 year+78.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

CAD · from the income statement

Latest · FY2025
(101.23M) CAD
Year-over-year change
+78.9%

Other Income / Expenses vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +61.9% is the highest of 9, against a peer median of -92.4%.
  • Other income / expenses amounts to 58.6% of revenue for CGC, versus a peer median of 69.5%.
CGC Competitors
Other Income / Expenses for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIOABioAge Labs, Inc.LTM Mar 2026$11.78M USD+9.2%+266.7%114.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$10.82M USD-0.5%+57.2%129.3%
CABACabaletta Bio, Inc.LTM Mar 2026$3.97M USD-46.9%+55.6%—
TKNOAlpha Teknova, Inc.LTM Mar 2026-$776K USD-286.1%—1.9%
ACBAurora Cannabis Inc.LTM Mar 2026-CA$5.83M CAD-137.8%—1.9%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026-$30.37M USD-4.6%—8.4%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$33.6M USD——24.9%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$54.54M USD-309.6%—175948.4%
CGCCanopy Growth CorporationLTM Mar 2026-CA$182.91M CAD+61.9%—58.6%
DHDefinitive Healthcare Corp.LTM Mar 2026-$398.43M USD-527.8%—167.2%
Peer median (excluding CGC) —-92.4%+57.2%69.5%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.